Drug intelligence / Profile preview

VEEBOSE-GM

Development stage
Unknown
Lead developer
Biomax Biotechnics
Modality
Small Molecules
Administration
Oral
01

Overview

VEEBOSE-GM is a fixed-dose combination oral anti-diabetic medication marketed by Biomax Biotechnics. It contains three active ingredients: acarbose and voglibose, which are alpha-glucosidase inhibitors, and metformin, a biguanide. Acarbose and voglibose work by inhibiting the alpha-glucosidase enzymes in the small intestine, thereby delaying the digestion and absorption of carbohydrates and reducing postprandial blood glucose levels. Metformin acts primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This combination is used for the management of type 2 diabetes mellitus, particularly when glycemic control is not achieved with monotherapy or dual therapy.

Brand names
VEEBOSE-GM
Other names
Acarbose + Voglibose + Metformin tablets
02

Targets

ND1 (Mitochondrial electron transport chain complex I)Sucrase-IsomaltaseAMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on VEEBOSE-GM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VEEBOSE-GM.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call